Safety and Immunogenicity of Typhax, a Typhoid Vaccine

Overview

This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.

Full Title of Study: “A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Trial to Determine the Safety and Immunogenicity of Typhax Delivered IM”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 15, 2017

Detailed Description

Healthy adult subjects aged 18 to 55 years were assigned to 3 ascending dose cohorts of Typhax (0.5, 2.5 or 10 mcg Vi antigen). Groups of 15 subjects in each dose cohort were randomized to receive Typhax, Typhim Vi (25 mcg Vi antigen) or placebo (saline) in a ratio of 3:1:1, respectively. Typhax and placebo (saline) was administered as two dose regimen (Days 0 and 28), and Typhim Vi was given as a single dose (Day 0) with matching placebo on Day 28. All doses were administered by a unblinded third-party as 0.5 mL by intramuscular (IM) injection. Safety and reactogenicity endpoints was assessed at 14 and 28 days after the first Typhax vaccination and 14 days after the second vaccination. Immunogenicity was assessed using an enzyme-linked immunosorbent assay (ELISA) to measure anti-Vi antibody serum titers on days 0, 14, 28, 42 and 180. A positive immune response (seroconversion) by ELISA is defined as at least a 4-fold increase over baseline in the Vi-specific ELISA.

Interventions

  • Biological: Typhax (investigational typhoid fever candidate vaccine)
  • Biological: Placebo
    • Placebo is administered to the control group on Day 0 and 28
  • Biological: Active Comparator Typhim Vi
    • A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28

Arms, Groups and Cohorts

  • Experimental: Typhax 0.5 mcg
    • Vaccine was administered IM on Days 0 and 28 (n=9).
  • Experimental: Typhax 2.5 mcg
    • Vaccine was administered IM on Days 0 and 28 (n=9).
  • Experimental: Typhax 10 mcg
    • Vaccine was administered IM on Days 0 and 28 (n=9).
  • Active Comparator: Typhim Vi 25 mcg
    • Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
  • Placebo Comparator: Placebo (saline)
    • Placebo control was administered IM Days 0 and 28 ( n=9)

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants reporting solicited injection site and systemic events and unsolicited adverse events following vaccination with Typhax
    • Time Frame: Days 0 up to Day 56 (= 28 Days post second vaccination)
    • Solicited Injection Site reactions: Pain, Tenderness, Erythema, Induration; Solicited Systemic Reactions Fever, Headache, Joint Pain, Joint Swelling, Fatigue, Myalgia, Nausea, Vomiting, Diarrhea
  • Number of participants reporting adverse events following vaccination with Typhax
    • Time Frame: Days 0 up to Day 210
    • Adverse events are assessed at study visits by PI for seriousness, relationship to investigational product , severity and other possible etiologies
  • Anti-Vi IgG antibody seroconversion and geometric mean antibody titers
    • Time Frame: Day 0 – Day 14
    • The immunogenicity will be measured by ELISA for anti-Vi percent seroconversion and GMTs before and at day 14 after vaccination.
  • Anti-Vi IgG antibody seroconversion and geometric mean antibody titers
    • Time Frame: Day 0 – Day 28
    • The immunogenicity will be measured by ELISA for anti-Vi percent seroconversion and GMTs before and at day 28 after vaccination.
  • Anti-Vi IgG antibody seroconversion and geometric mean antibody titers
    • Time Frame: Day 0 – Day 42
    • The immunogenicity will be measured by ELISA for anti-Vi percent seroconversion and GMTs before and at day 42.
  • Anti-Vi IgG antibody seroconversion and geometric mean antibody titers
    • Time Frame: Day 0 – Day 180.
    • The immunogenicity will be measured by ELISA for anti-Vi percent seroconversion and GMTs before and at day 180.

Secondary Measures

  • Vi-specific B-cell ELISPOT responses
    • Time Frame: Days 0 through 38
    • Immunogenicity was evaluated by comparing the number of Vi-specific B-cells by ELISPOT in PBMC samples

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy adult men or women who are not pregnant or planning to become pregnant during study duration aged 18 to 55 years. – Clinical laboratory parameters within normal laboratory limits or not found to be clinically significant by the PI Exclusion Criteria:

  • Relevant history of physical or psychiatric illness or medical disorder that required treatment. – Known or suspected hypersensitivity to investigational product – Immunocompromised subjects – Previous Typhoid vaccination or elevated anti-Vi antibodies at screening – Known history of Typhoid infection in the previous 6 months – Positive HIV, HBsAg, or HCV screen – Any other condition or abnormality that, in the opinion of the Investigator, may compromise the safety of the patients

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Matrivax Research and Development Corporation
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.